DGAP-News: Sangui BioTech International Inc.: Revenues slightly improved in the first quarter of the 2014 financial year
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter
Results
Sangui BioTech International Inc.: Revenues slightly improved in the
first quarter of the 2014 financial year
06.11.2013 / 14:30
---------------------------------------------------------------------
Sangui BioTech: Revenues slightly improved in the first quarter of the 2014
financial year
Research and development for new patent application, preparation of animal
test
Witten, Germany, November 6, 2013
For the first quarter (as of September 30, 2013) of its 2014 financial year
Sangui BioTech International, Inc. reports revenues from product sales and
royalties in the amount of USD26.527 (Q1/2014: USD1.794). This is an
improvement of 10% as compared with the fourth quarter of the previous
financial year (as of June 30, 2013).
Research and development expenses amounted to USD36.308 (Q1/2013: USD
8.444). The increase is due to the preparations made for filing a new
patent application as well as of animal testing aimed at demonstrating the
functionality of Sangui's technology with respect to various indications.
The net loss attributable to shareholders of the parent company came to
USD172.202 (Q1/2013: USD180.205), the cash outflow from operations during
the quarter amounted to USD189.860 (Q1/2013: USD204.473).
As of September 30, 2013, the equity ratio was 70.5% (September 30, 2012:
56.7%).
After the end of the quarter the shareholders of SastoMed GmbH resolved to
swap the shareholder loans outstanding for equity preserving their
respective share in the stock of the company. SanguiBioTech GmbH holds 25%
in SastoMed GmbH, Sangui has granted SastoMed the global distribution
rights for the wound therapeutic Granulox.
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
06.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
237981 06.11.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2013 - 14:30 Uhr
Sprache: Deutsch
News-ID 313335
Anzahl Zeichen: 3500
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 278 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Revenues slightly improved in the first quarter of the 2014 financial year"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
